Timothy F. Burns, MD, PhD, discusses the necessary role of next-generation sequencing testing in patients with lung adenocarcinoma. In order to incorporate this into clinical practice, there is still a lot more work to be done, Burns says. Around 20% to 25% of patients with adenocarcinoma have targetable alterations.
Timothy F. Burns, MD, PhD, an assistant professor of medicine at the University of Pittsburgh Cancer Institute, discusses the necessary role of next-generation sequencing (NGS) testing in patients with lung adenocarcinoma. In order to incorporate this into clinical practice, there is still a lot more work to be done, Burns says. Around 20% to 25% of patients with adenocarcinoma have targetable alterations.
The University of Pittsburgh is a large referral center, so they see a lot of patients getting NGS, Burns says. However, many patients with adenocarcinoma will have limited panels performed and so they may not be tested for all necessary mutations or translocations that could help determine the best treatment.
Burns says that even panels that are sent to Foundation Medicine to be tested may not cover enough. RNA sequencing data are important for detecting fusions as well, Burns adds. He warns that if an oncologist’s institution does not have the capability to conduct fluorescence in situ hybridization (FISH) testing, or use other technologies, many translocations and alterations could be missed.
In Real-World Analyses, Apalutamide Delivers Quicker Responses in Prostate Cancer
June 15th 2024Benjamin Lowentritt, MD, discussed findings from real-world analyses looking at enzalutamide or abiraterone vs apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
Successes With T-DXd and the Need for Continued Research in Brain Metastasis
June 13th 2024In an interview with Targeted Oncology, Sarah Sammons, MD, discussed an analysis of the DESTINY-Breast03 trial, highlighting the need for further research on trastuzumab deruxtecan in other breast cancer subtypes and solid tumors with brain metastases.
Read More